Infertility, ovulation, induced ovulation, and female cancers

European Journal of Cancer Prevention

Volumn 20, Issue 3, 2011, Pages 147-149

  La Vecchia, Carlo ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE; GONADOTROPIN DERIVATIVE; ORAL CONTRACEPTIVE AGENT;

ANOVULATION; BREAST CANCER; CANCER RISK; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; FEMALE INFERTILITY; HIGH RISK POPULATION; HUMAN; MENARCHE; OVARY CANCER; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INFERTILITY; OVULATION;

EID: 79955064739     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834474dc     Document Type: Review

References (27)

1. Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, et al. (2005). Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 161:607-615. (Pubitemid 40411088)
2. Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ (2005). Ovulation induction and cancer risk. Fertil Steril 83:261-274. quiz 525-266. (Pubitemid 40221776)
3. Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG, et al. (2003). Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 79:844-851. (Pubitemid 36385001)
4. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE (1979). 'Incessant ovulation' and ovarian cancer. Lancet 2:170-173.
5. Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, et al. (2001). Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12:337-341. (Pubitemid 32288689)
6. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684-1692.
7. Dos Santos Silva I,Wark PA, McCormack VA, Mayer D, Overton C, Little V, et al. (2009). Ovulation-stimulation drugs and cancer risks: a long-term ollow-up of a British cohort. Br J Cancer 100:1824-1831.
8. Eden JA (2010). Breast cancer, stem cells and sex hormones. Part 2: the impact of the reproductive years and pregnancy. Maturitas 67:215-218.
9. Fathalla MF (1971). Incessant ovulation - a factor in ovarian neoplasia? Lancet 2:163.
10. Fisher B, Costantino JP,Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388. (Pubitemid 28439961)
11. Jensen A, Sharif H, Kjaer SK (2009). Use of fertility drugs and risk of uterine cancer: results from a large Danish population-based cohort study. Am J Epidemiol 170:1408-1414.
12. Klip H, Burger CW, Kenemans P, Van Leeuwen FE (2000). Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 11:319-344. (Pubitemid 30255874)
13. La Vecchia C, Franceschi S, Gallus G, Decarli A, Liberati A, Tognoni G (1983). Incessant ovulation and ovarian cancer: a critical approach. Int J Epidemiol 12:161-164. (Pubitemid 13027593)
14. La Vecchia C, Decarli A, Di Pietro S, Franceschi S, Negri E, Parazzini F (1985). Menstrual cycle patterns and the risk of breast disease. Eur J Cancer Clin Oncol 21:417-422. (Pubitemid 15076945)
15. Lerner-Geva L, Rabinovici J, Lunenfeld B (2010). Ovarian stimulation: is there a long-term risk for ovarian, breast and endometrial cancer? Womens Health (Lond Engl) 6:831-839.
16. Norman RJ (2001). Obesity, polycystic ovary syndrome and anovulation - how are they interrelated? Curr Opin Obstet Gynecol 13:323-327. (Pubitemid 32673534)
17. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S (1991). The epidemiology of endometrial cancer. Gynecol Oncol 41:1-16.
18. Parazzini F, Pelucchi C, Negri E, Franceschi S, Talamini R, Montella M, et al. (2001a). Use of fertility drugs and risk of ovarian cancer. Hum Reprod 16:1372-1375. (Pubitemid 32640310)
19. Parazzini F, Ricci E, Rosa C, Negri E, La Vecchia C (2001b). Risk of endometrial cancer after use of fertility drugs. Hum Reprod 16:196. (Pubitemid 32058606)
20. Parazzini F, Pelucchi C, Talamini R, Montella M, La Vecchia C (2010). Use of fertility drugs and risk of endometrial cancer in an Italian case-control study. Eur J Cancer Prev 19:428-430.
21. Pelucchi C, Galeone C, Talamini R, Bosetti C, Montella M, Negri E, et al. (2007). Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 196:83e81-87e81.
22. Talamini R, Franceschi S, La Vecchia C, Negri E, Borsa L, Montella M, et al. (1996). The role of reproductive and menstrual factors in cancer of the breast before and after menopause. Eur J Cancer 32A:303-310.
23. Terry KL, Willett WC, Rich-Edwards JW, Hunter DJ, Michels KB (2005). Menstrual cycle characteristics and incidence of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14:1509-1513. (Pubitemid 40807354)
24. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, et al. (2003). Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158:629-638. (Pubitemid 37175510)
25. Venn A,Watson L, Bruinsma F, Giles G, Healy D (1999). Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354:1586-1590. (Pubitemid 29515949)
26. Whittemore AS, Harris R, Itnyre J; Collaborative Ovarian Cancer Group (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136:1184-1203. (Pubitemid 23026890)
27. Zucchetto A, Serraino D, Polesel J, Negri E, De Paoli A, Dal Maso L, et al. (2009). Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev 18:316-321.